The global market for pet OTC medication is poised for substantial growth, with an estimated valuation of US$ 9,170 million in 2023. This market exhibits a robust trend, characterized by a CAGR of 4.5% expected to persist until 2033
Steadfast growth projections suggest that the global share of the pet OTC medication market is on track to reach an impressive valuation of US$ 14,210.2 million by the year 2033.
Key Market Trends and Highlights
| Attributes | Key Insights |
|---|---|
| Pet OTC Medication Market Value in 2023 | US$ 9,170 million |
| Projected Market Value in 2033 | US$ 14,210.2 million |
| Value-based CAGR from 2023 to 2033 | 4.5% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The scope for global pet OTC medication market insights rose at a 3.46% CAGR between 2018 and 2022. The global market for global pet OTC medication value is anticipated to develop at a moderate CAGR of 4.5% over the forecast period from 2023 to 2033.
| Report Attributes | Details |
|---|---|
| Market Value in 2018 | US$ 7,720 million |
| Market Value in 2022 | US$ 8,845.7 million |
| CAGR from 2018 to 2022 | 3.46% |
The global pet OTC medication market exhibited steady growth from 2018 to 2022. This period witnessed a gradual expansion in the market, driven primarily by the rising number of pet adoptions and a growing awareness about pet health among consumers worldwide.
Key market players predominantly focused their efforts on established markets in Europe and North America, capitalizing on the high demand for pet medicines in countries such as the United States, Canada, the United Kingdom, Germany, and Italy. Pet OTC medications became widely available in these regions during this period and consumers became increasingly informed about these products, driving market growth.
Market players strategically positioned themselves to cater to the growing demand for pet healthcare products in these well-established markets. The market is further expected to maintain its growth trajectory from 2023 to 2033.
The global pet OTC medication market is projected to continue expanding steadily, with key determinants of revenue growth including
There is an increasing focus on exploring untapped opportunities in emerging markets across Asia, the Middle East, and Africa as the market reaches maturity in established regions. Emerging firms are eyeing these regions as potential growth areas, seeking to establish a brand presence while these markets are still in the developing phase.
The pet OTC medication market witnessed stable growth from 2018 to 2022, driven by factors such as pet adoption trends and increased awareness of pet health. The market is expected to continue its positive trajectory from 2023 to 2033, with opportunities for expansion in emerging markets as the industry evolves.
Principal Consultant
The below table showcases revenues in terms of the five countries, spearheaded by the United States, China, the United Kingdom, Japan, and India. Out of these 5 countries, the United States is leading followed by China.
Expected Market Values in 2033
| The United States | US$ 11,210 million |
|---|---|
| India | US$ 4,821.2 million |
| France | US$ 7,120 million |
| China | US$ 9,688.9 million |
| Germany | US$ 6,145 million |
The pet OTC medication market in the United States stands as one of the most prosperous segments globally, with a current valuation of US$ 11,210 million and a steady sales growth rate at a market share of 49.3% by 2033.
The financial robustness can be attributed to the country's well-established and mature customer base, known for its significant expenditures on pet care products, accessories, toys, and, notably, medications. The United States pet owners' dedication to their pets' health and well-being has translated into a consistently growing demand for over-the-counter pet medications.
One noteworthy factor further propelling the market's growth is the surge in pet insurance offerings within the United States. The increasing adoption of pet insurance plans makes OTC medications accessible to a broad spectrum of consumers.
The financial burden of pet healthcare diminishes, prompting them to seek and invest in a wider range of pet health products, including OTC medications as pet owners opt for insurance coverage. This trend is expected to be a significant driver in augmenting the market's growth trajectory, catering to a diverse consumer base, and fostering increased sales of pet OTC medications.
France is anticipated to reach US$ 7,120 million by 2033 and expand at a market share of 3.7% by 2033.
The strong presence of France in the global pharmaceutical industry positions it as a significant player in the pet OTC medication market. The country's reputation for innovation and research excellence has attracted leading pharmaceutical firms, turning it into a hub for launching new pet healthcare products. With a focus on pet health and well-being, the pet OTC medication market in France is expected to thrive.
Key market players, including Vetoquinol SA and Virbac SA Co, are headquartered in France, further solidifying the nation's importance in the industry. These renowned pharmaceutical companies have a global presence and leverage their expertise to develop high-quality pet medications.
The presence of renowned companies in France not only supports the local market but also contributes to the growth of the pet OTC medicine sector in Europe. With innovation at its core, France is poised to play a pivotal role in shaping the future of pet healthcare and driving market expansion.
The pet OTC medication market in India is experiencing significant growth, with a current valuation of US$ 4,821.2 million and a projected market share of 1.6%.
The growth is primarily driven by the increasing adoption of pets across the country and the growing awareness among consumers regarding pet healthcare. As many Indian households welcome pets into their homes, the demand for over-the-counter medications to ensure the well-being of these animals is on the rise.
The rise in pet adoption can be attributed to various factors, including changing lifestyles, increased disposable income, and a cultural shift toward pet ownership. This trend is particularly prominent in urban areas, where the concept of pet companionship is gaining traction. As many people in India embrace pets as part of their families, the need for accessible and effective pet OTC medications is becoming paramount.
The market presents a significant opportunity for both established and emerging players in the pet OTC medication market in India to cater to the evolving demands of pet owners and contribute to the overall growth of the industry.
The pet supplement market is poised for substantial growth in the coming years, with a projected market share of 5.1% with a valuation of US$ 9,688.9 million by 2033. One of the key drivers fueling this growth is the changing perception among pet owners who increasingly recognize that standard pet food may not fully meet their pets' health needs.
The shift in mindset is creating a favorable environment for pet supplements, which are seen as a means to address any nutritional deficiencies in pets' daily diets effectively. Also, the growing population of domesticated animals, including dogs, fish, birds, and cats, particularly in regions like China, is expected to drive robust demand for pet supplements.
Pet owners are becoming conscious of their pets' health and well-being as pet ownership continues to rise. Consequently, this drives the demand for supplements that can support their pets' overall health, vitality, and longevity. This trend is expected to be a significant factor in the continued expansion of the pet supplement market in the coming years.
OTC veterinary drug market in Germany registered a market share of 4.5% with a valuation of US$ 6,145 million by 2033.
The rising rate of pet adoption and the trend of pet humanization is one of the primary drivers of market expansion. Pet owners are increasingly considering their pets as family members, leading to a surge in demand for high-quality pet care products, including OTC veterinary drugs. The heightened pet adoption is not only boosting the sales of OTC veterinary drugs but also enhancing the overall market dynamics.
The region benefits from the presence of leading OTC veterinary drug producers, such as Merck Animal Health, Boehringer Ingelheim, and Virbac S.A. These industry leaders contribute to the high availability of veterinary drug products within the country.
The robust presence of the key players is bolstering market growth and ensuring a wide range of OTC veterinary drugs for pet owners, veterinarians, and the broader pet care industry.
The below table highlights how dogs and fleas and ticks are projected to lead the pet OTC medication market expanding at a market share of 35% and 43.1% through 2033 respectively. The table further continues with the details about how the chewables & tablets are likely to spearhead sales based on source and are anticipated to witness a market share of 30% through 2033.
| Category | Market Share by 2033 |
|---|---|
| Dogs | 35% |
| Fleas & Ticks | 43.1% |
| Chewables & Tablets | 30% |
The dog OTC medication category currently claims a substantial 35% share of the overall market, translating to a market value of US$ 3,400 million.
A notable surge in pet adoption was primarily driven by the emergence of a pet-parent culture in developed nations. This cultural shift toward considering pets as cherished family members has significantly impacted the pet care industry. Among the various segments within the market, dog over-the-counter (OTC) medications have emerged as the top-selling category, accounting for the lion's share of sales.
The dominance can be attributed to the growing number of dog owners who prioritize their pets' health and well-being. As pet parents increasingly seek accessible and effective healthcare solutions for their canine companions, the demand for OTC medications tailored for dogs has soared. This trend reflects the significant influence of the pet-parent culture on consumer behavior and purchasing decisions in the pet care industry.
Fleas & ticks claim a substantial 43.1% share of the overall market, translating to a market value of US$ 1,580 million.
The pet OTC medication market is experiencing a significant boost in growth, primarily fueled by rising pet adoption rates and pet owners' willingness to invest in the health and well-being of their furry companions. As many households welcome pets into their families, the demand for pet care products, including flea and tick treatments, is on the rise.
Pet owners are increasingly conscious of the importance of protecting their pets from common parasites like fleas and ticks, which can cause discomfort and health issues. This heightened awareness is driving pet owners to seek over-the-counter medications that provide effective and convenient solutions for parasite control.
The growing awareness about pet parasitism is playing a pivotal role in the market's expansion. Pet owners are proactively seeking information about the risks associated with parasites and are keen on preventing infestations. The shift toward preventive care aligns with the broad trend of pet humanization, where pets are regarded as cherished family members deserving of the best possible care.
Based on form, the chewables & tablets are anticipated to dominate the industry with a market share of 30% by 2033.
Administering medications to pets can often be a challenging task for pet owners. Recognizing this common struggle, many manufacturers have shifted their focus toward offering over-the-counter (OTC) pet medications in convenient forms such as chews and tablets.
The transformation is driven by the desire to simplify the medication process, making it accessible and enjoyable for both pets and their owners. Chewables and tablets have gained popularity, emerging as preferred choices for pet owners seeking effective and hassle-free ways to care for their furry companions.
Chewable medications, resembling treats in appearance and taste, have emerged as a favored option among pet owners. These chewables not only make the administration of medicines manageable but also transform it into a rewarding experience for pets. The innovative approach ensures that pets willingly accept their medication, addressing a significant challenge that pet owners frequently encounter.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Prices for raw materials are predicted to fluctuate, and new techniques followed by competitors will present a big challenge for established businesses. They are spending money on research and development, and innovation to keep reinforce their position in the pet OTC medication market.
Key players rely on mergers, acquisitions, and joint ventures to protect their position and lower system costs. To suit the demands of innovative design, they offer structural design and construction services. Some market entrants are discussed below.
| Attributes | Details |
|---|---|
| Estimated Market Size in 2023 | US$ 9,170 million |
| Projected Market Valuation in 2033 | US$ 14,210.2 million |
| CAGR Share from 2023 to 2033 | 4.5% |
| Forecast Period | 2023 to 2033 |
| Historical Data Available for | 2018 to 2022 |
| Market Analysis | Value in US$ million |
| Key Regions Covered | North America; Latin America; Western Europe; Eastern Europe; South Asia and Pacific; East Asia; The Middle East & Africa |
| Key Market Segments Covered | Pet Type, Application, Form, Sales Channel, Region |
| Key Countries Profiled | The United States, Canada, Brazil, Mexico, Germany, The United Kingdom, France, Spain, Italy, Russia, Poland, Czech Republic, Romania, India, Bangladesh, Australia, New Zealand, China, Japan, South Korea, GCC countries, South Africa, Israel |
| Key Companies Profiled | Ceva Santé Animale Co.; Elanco Animal Health Inc.; Boehringer Ingelheim International GmbH; Zoetis Inc.; Merck & Co., Inc.; Virbac SA Co.; Bayer AG; IDEXX Laboratories Co.; Covetrus Inc.; Dechra Pharmaceuticals PLC; Vetoquinol SA; Phibro Animal Health Co.; Kyoritsuseiyaku Co.; Krka, d. d., Novo Mesto; Sequent Scientific Ltd.; Heska Co.; Eco Animal Health Group |
The pet OTC medication market is expected to reach US$ 9,170 million in 2023.
The pet OTC medication market is set to expand by a CAGR of 4.5% by 2033.
The pet OTC medication industry is forecast to reach US$ 14,210.2 million by 2033.
The United States is likely to be the top-performing market, accounting for US$ 11,210 million by 2033.
Fleas & ticks are preferred and are expected to rise at a market share of 43.1% through 2033.
1. Executive Summary
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Supply Chain Analysis
3.5.1. Supply Side Participants and their Roles
3.5.1.1. Producers
3.5.1.2. Mid-Level Participants (Traders/ Agents/ Brokers)
3.5.1.3. Wholesalers and Distributors
3.5.2. Value Added and Value Created at Node in the Supply Chain
3.5.3. List of Raw Material Suppliers
3.5.4. List of Existing and Potential Buyer’s
3.6. Investment Feasibility Matrix
3.7. Value Chain Analysis
3.7.1. Profit Margin Analysis
3.7.2. Wholesalers and Distributors
3.7.3. Retailers
3.8. PESTLE and Porter’s Analysis
3.9. Regulatory Landscape
3.9.1. By Key Regions
3.9.2. By Key Countries
3.10. Regional Parent Market Outlook
3.11. Production and Consumption Statistics
3.12. Import and Export Statistics
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) & Volume (Units) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) & Volume (Units) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Pet Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Pet Type, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Pet Type, 2023 to 2033
5.3.1. Dogs
5.3.2. Cats
5.3.3. Birds
5.3.4. Fish and Reptiles
5.3.5. Small Pets
5.3.6. Others
5.4. Y-o-Y Growth Trend Analysis By Pet Type, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Pet Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Application
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Application, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Application, 2023 to 2033
6.3.1. Fleas & Ticks
6.3.2. Allergies
6.3.3. Pain Relief & Arthritis
6.3.4. De-wormers
6.3.5. Others
6.4. Y-o-Y Growth Trend Analysis By Application, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Application, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Form
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Form, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Form, 2023 to 2033
7.3.1. Chewables & Tablets
7.3.2. Capsules & Ointment
7.3.3. Sprays
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By Form, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By Form, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Sales Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Sales Channel, 2018 to 2022
8.3. Current and Future Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Sales Channel, 2023 to 2033
8.3.1. Pet Specialty Stores
8.3.2. Veterinary Clinics
8.3.3. Drug & Pharmacy Stores
8.3.4. Online Retail
8.3.5. Others
8.4. Y-o-Y Growth Trend Analysis By Sales Channel, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Sales Channel, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ Million) & Volume (Units) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ Million) & Volume (Units) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Western Europe
9.3.4. Eastern Europe
9.3.5. South Asia and Pacific
9.3.6. East Asia
9.3.7. Middle East and Africa
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. The USA
10.2.1.2. Canada
10.2.2. By Pet Type
10.2.3. By Application
10.2.4. By Form
10.2.5. By Sales Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Pet Type
10.3.3. By Application
10.3.4. By Form
10.3.5. By Sales Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Pet Type
11.2.3. By Application
11.2.4. By Form
11.2.5. By Sales Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Pet Type
11.3.3. By Application
11.3.4. By Form
11.3.5. By Sales Channel
11.4. Key Takeaways
12. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. United Kingdom
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Western Europe
12.2.2. By Pet Type
12.2.3. By Application
12.2.4. By Form
12.2.5. By Sales Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Pet Type
12.3.3. By Application
12.3.4. By Form
12.3.5. By Sales Channel
12.4. Key Takeaways
13. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. Poland
13.2.1.2. Russia
13.2.1.3. Czech Republic
13.2.1.4. Romania
13.2.1.5. Rest of Eastern Europe
13.2.2. By Pet Type
13.2.3. By Application
13.2.4. By Form
13.2.5. By Sales Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Pet Type
13.3.3. By Application
13.3.4. By Form
13.3.5. By Sales Channel
13.4. Key Takeaways
14. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. India
14.2.1.2. Bangladesh
14.2.1.3. Australia
14.2.1.4. New Zealand
14.2.1.5. Rest of South Asia and Pacific
14.2.2. By Pet Type
14.2.3. By Application
14.2.4. By Form
14.2.5. By Sales Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Pet Type
14.3.3. By Application
14.3.4. By Form
14.3.5. By Sales Channel
14.4. Key Takeaways
15. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. China
15.2.1.2. Japan
15.2.1.3. South Korea
15.2.2. By Pet Type
15.2.3. By Application
15.2.4. By Form
15.2.5. By Sales Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Pet Type
15.3.3. By Application
15.3.4. By Form
15.3.5. By Sales Channel
15.4. Key Takeaways
16. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ Million) & Volume (Units) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ Million) & Volume (Units) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Pet Type
16.2.3. By Application
16.2.4. By Form
16.2.5. By Sales Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Pet Type
16.3.3. By Application
16.3.4. By Form
16.3.5. By Sales Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Pet Type
17.1.2.2. By Application
17.1.2.3. By Form
17.1.2.4. By Sales Channel
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Pet Type
17.2.2.2. By Application
17.2.2.3. By Form
17.2.2.4. By Sales Channel
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Pet Type
17.3.2.2. By Application
17.3.2.3. By Form
17.3.2.4. By Sales Channel
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Pet Type
17.4.2.2. By Application
17.4.2.3. By Form
17.4.2.4. By Sales Channel
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Pet Type
17.5.2.2. By Application
17.5.2.3. By Form
17.5.2.4. By Sales Channel
17.6. United Kingdom
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Pet Type
17.6.2.2. By Application
17.6.2.3. By Form
17.6.2.4. By Sales Channel
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Pet Type
17.7.2.2. By Application
17.7.2.3. By Form
17.7.2.4. By Sales Channel
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Pet Type
17.8.2.2. By Application
17.8.2.3. By Form
17.8.2.4. By Sales Channel
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Pet Type
17.9.2.2. By Application
17.9.2.3. By Form
17.9.2.4. By Sales Channel
17.10. Poland
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Pet Type
17.10.2.2. By Application
17.10.2.3. By Form
17.10.2.4. By Sales Channel
17.11. Russia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Pet Type
17.11.2.2. By Application
17.11.2.3. By Form
17.11.2.4. By Sales Channel
17.12. Czech Republic
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Pet Type
17.12.2.2. By Application
17.12.2.3. By Form
17.12.2.4. By Sales Channel
17.13. Romania
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Pet Type
17.13.2.2. By Application
17.13.2.3. By Form
17.13.2.4. By Sales Channel
17.14. India
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Pet Type
17.14.2.2. By Application
17.14.2.3. By Form
17.14.2.4. By Sales Channel
17.15. Bangladesh
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Pet Type
17.15.2.2. By Application
17.15.2.3. By Form
17.15.2.4. By Sales Channel
17.16. Australia
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Pet Type
17.16.2.2. By Application
17.16.2.3. By Form
17.16.2.4. By Sales Channel
17.17. New Zealand
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Pet Type
17.17.2.2. By Application
17.17.2.3. By Form
17.17.2.4. By Sales Channel
17.18. China
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Pet Type
17.18.2.2. By Application
17.18.2.3. By Form
17.18.2.4. By Sales Channel
17.19. Japan
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Pet Type
17.19.2.2. By Application
17.19.2.3. By Form
17.19.2.4. By Sales Channel
17.20. South Korea
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Pet Type
17.20.2.2. By Application
17.20.2.3. By Form
17.20.2.4. By Sales Channel
17.21. GCC Countries
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Pet Type
17.21.2.2. By Application
17.21.2.3. By Form
17.21.2.4. By Sales Channel
17.22. South Africa
17.22.1. Pricing Analysis
17.22.2. Market Share Analysis, 2022
17.22.2.1. By Pet Type
17.22.2.2. By Application
17.22.2.3. By Form
17.22.2.4. By Sales Channel
17.23. Israel
17.23.1. Pricing Analysis
17.23.2. Market Share Analysis, 2022
17.23.2.1. By Pet Type
17.23.2.2. By Application
17.23.2.3. By Form
17.23.2.4. By Sales Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Pet Type
18.3.3. By Application
18.3.4. By Form
18.3.5. By Sales Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Ceva Santé Animale Co.
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.1.5.2. Product Strategy
19.1.1.5.3. Channel Strategy
19.1.2. Elanco Animal Health Inc.
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.2.5.2. Product Strategy
19.1.2.5.3. Channel Strategy
19.1.3. Boehringer Ingelheim International GmbH
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.3.5.2. Product Strategy
19.1.3.5.3. Channel Strategy
19.1.4. Zoetis Inc.
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.4.5.2. Product Strategy
19.1.4.5.3. Channel Strategy
19.1.5. Merck & Co., Inc.
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.5.5.2. Product Strategy
19.1.5.5.3. Channel Strategy
19.1.6. Virbac SA Co.
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.6.5.2. Product Strategy
19.1.6.5.3. Channel Strategy
19.1.7. Bayer AG
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.7.5.2. Product Strategy
19.1.7.5.3. Channel Strategy
19.1.8. IDEXX Laboratories Co.
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.8.5.2. Product Strategy
19.1.8.5.3. Channel Strategy
19.1.9. Covetrus Inc.
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.9.5.2. Product Strategy
19.1.9.5.3. Channel Strategy
19.1.10. Dechra Pharmaceuticals PLC
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.10.5.2. Product Strategy
19.1.10.5.3. Channel Strategy
19.1.11. Vetoquinol SA
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
19.1.11.5.2. Product Strategy
19.1.11.5.3. Channel Strategy
19.1.12. Phibro Animal Health Co.
19.1.12.1. Overview
19.1.12.2. Product Portfolio
19.1.12.3. Profitability by Market Segments
19.1.12.4. Sales Footprint
19.1.12.5. Strategy Overview
19.1.12.5.1. Marketing Strategy
19.1.12.5.2. Product Strategy
19.1.12.5.3. Channel Strategy
19.1.13. Kyoritsuseiyaku Co.
19.1.13.1. Overview
19.1.13.2. Product Portfolio
19.1.13.3. Profitability by Market Segments
19.1.13.4. Sales Footprint
19.1.13.5. Strategy Overview
19.1.13.5.1. Marketing Strategy
19.1.13.5.2. Product Strategy
19.1.13.5.3. Channel Strategy
19.1.14. Krka, d. d., Novo Mesto
19.1.14.1. Overview
19.1.14.2. Product Portfolio
19.1.14.3. Profitability by Market Segments
19.1.14.4. Sales Footprint
19.1.14.5. Strategy Overview
19.1.14.5.1. Marketing Strategy
19.1.14.5.2. Product Strategy
19.1.14.5.3. Channel Strategy
19.1.15. Sequent Scientific Ltd.
19.1.15.1. Overview
19.1.15.2. Product Portfolio
19.1.15.3. Profitability by Market Segments
19.1.15.4. Sales Footprint
19.1.15.5. Strategy Overview
19.1.15.5.1. Marketing Strategy
19.1.15.5.2. Product Strategy
19.1.15.5.3. Channel Strategy
19.1.16. Heska Co.
19.1.16.1. Overview
19.1.16.2. Product Portfolio
19.1.16.3. Profitability by Market Segments
19.1.16.4. Sales Footprint
19.1.16.5. Strategy Overview
19.1.16.5.1. Marketing Strategy
19.1.16.5.2. Product Strategy
19.1.16.5.3. Channel Strategy
19.1.17. Eco Animal Health Group
19.1.17.1. Overview
19.1.17.2. Product Portfolio
19.1.17.3. Profitability by Market Segments
19.1.17.4. Sales Footprint
19.1.17.5. Strategy Overview
19.1.17.5.1. Marketing Strategy
19.1.17.5.2. Product Strategy
19.1.17.5.3. Channel Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Consumer Product Insights
View Reports
Pet OTC Medication Market
